Develops and sells ophthalmic devices for diagnosing and treating eye diseases. Provides systems and consumables for cataract, retinal, and refractive surgeries. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Every year shown ended in profit.
The gap is $122.0M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 81% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.63 per share each year — regular cash for whoever holds the stock.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.